诺和诺德推现金支付优惠，Ozempic美国月费从千元降至499美元

Core Viewpoint - Novo Nordisk has announced a significant price reduction for Ozempic, targeting patients who pay out-of-pocket, as the drug has become a symbol of high drug prices in the U.S. [1] Group 1: Price Reduction Details - Patients can now purchase Ozempic through NovoCare for $499 per month, approximately half of the market price in the U.S. [1] - Novo Nordisk has partnered with GoodRx to offer the reduced price of $499 per month for both Ozempic and Wegovy across the U.S. [1] Group 2: Target Audience and Accessibility - The price reduction specifically targets patients without insurance or those whose insurance does not cover Ozempic, aiming to improve medication accessibility [2] - Ozempic is widely covered by insurance for diabetes treatment, meaning most patients do not pay the original price [2] Group 3: Market Context and Competition - The price cut comes amid competition pressure due to a shortage of supply, leading many patients to use cheaper generic alternatives [3] - Prior to the price reduction announcement, Eli Lilly, a major competitor, raised the price of its weight loss drug by up to 170% in the UK [2]